- دعاء اليوم
- حكمة اليوم
- أصبحنا وأصبح الملك لله وحده لاشريك له, له الملك وله الحمد وهو على كل شيئ قدير.- أعوذ بالله السميع العليم من... |
| قال لقمان لإبنه ثلاثة لا يعرفون إلا في ثلاثة مواطن قال لقمان لإبنه ثلاثة لا يعرفون إلا في ثلاثة مواطنلا يعرف الحليم إلا عند الغضبولا الشجاع إلا في الحرب إذا لقي الأقرانولا أخاك... |




Novartis announced Friday that it will cut around 1960 jobs in the US as part of a restructuring of its general medicines business in preparation for the loss of patent exclusivity on Diovan (valsartan) in the US in September. The company said it will also record charges totalling more than $1.2 billion due in part to a "reassessment of the future sales potential" of Rasilez (aliskiren) following termination of the ALTITUDE study last year.The drugmaker indicated that it will record an exceptional charge of approximately $ ...
Final draft guidance published Friday by the National Institute for Health and Clinical Excellence confirmed an earlier recommendation supporting NHS reimbursement of Eli Lilly, Amylin and Alkermes' Bydureon (extended-release exenatide) for certain people with type 2 diabetes. The agency said the once-weekly GLP-1 receptor agonist could be given in combination with certain other drugs in obese patients with a body mass index above 35, or those for whom insulin injections wouldn't be suitable. (Ref: NICE, Morningstar) ...
AstraZeneca announced two licensing deals Wednesday to bolster its drug pipeline, a day after reporting that it will record a charge of $381.5 million related to setbacks for other experimental compounds.Under the first agreement, AstraZeneca obtained an option from Astellas' Prosidion unit to acquire the two G protein-coupled receptor GPR119 agonists PSN821 and PSN842, which are being developed to treat type 2 diabetes. AstraZeneca will pay an undisclosed option fee, and in the event it acquires the oral drugs, will pay Pr ...
The National Institute for Health and Clinical Excellence issued final guidance Wednesday, recommending against NHS reimbursement of Novartis' Lucentis (ranibizumab) for the treatment of diabetic macular oedema (DMO). The drugmaker said it would "continue to work with NICE and the UK department of health toward a solution that will allow patients access" to the treatment.The decision, which confirmed a preliminary recommendation from the agency in July, was made after NICE's appraisal committee concluded that evidence prese ...
فارما جو – عمان أعلنت شركة أدوية الحكمة، وهي مجموعة شركات دوائية متعددة الجنسيات وتشهد نموا سريعا، عن افتتاحها شركة الدار العربية لصناعة الأدوية في الجزائر، وهي إحدى الشركات المملوكة من قبل شركة أدوية الحكمة، وثاني استثمار لها في الجزائر بعد شركة حكمة فارما الجزائر.جاء ذلك خلال مؤتمر صحفي عُقد في الجزائر للإعلان عن الافتتاح الذي تم يوم الثلاثاء 18 تشرين الأول (أكتوبر) الحالي، بحضور معالي الدكتور جمال ولد عباس وزير الصحة وإصلاح المستشفيات الجزائري، وتأسست شركة الدار العربية لصناعة الدواء كشركة متخصصة في صناعة المستحضرات الصيد ...
Takeda announced Friday a reduction of its full-year net income forecast by 32 percent due to costs related to the 9.6-billion euro ($13.3 billion) takeover of Nycomed and the stronger Japanese currency. Net income is expected to drop to 170 billion yen ($2.2 billion) in the 12 months ending March 2012, reflecting acquisition costs of 77 billion yen ($987 million).The drugmaker also reported that first-half net income slipped 5.9 percent compared to the year-earlier period to 135.7 billion yen ($1.7 billion), while sales fe ...
AstraZeneca reported Thursday that third-quarter net income jumped to $3.5 billion from $1.6 billion in the year-ago period, topping analysts' expectations of $3.2 billion, as the company recorded gains from the $1.8-billion divestment of its Astra Tech dental unit. Overall sales in the quarter rose 4 percent to $8.2 billion, led by "strong revenue growth" for Crestor, Seroquel and Symbicort, beating analyst estimates of $8.1 billion.CEO David Brennan remarked that the company "delivered a third quarter revenue…performance ...
فارما جو – عمان اقامت اللجنة الفرعية لصيادلة الزرقاء زيارة لاعضاء الهيئة العامة من صيادلة الزرقاء اصحاب الصيدليات والعاملين فيها بالاضافة الى صيادلة يعملون في المستشفيات الى مصنع شركة عمان للصناعات الدوائية API الكائن في سحاب وذلك يوم الاثنين 17/10/2011 .عدست فارما جو التقطت العديد من الصور التي غطت فعاليات زيارة وفد الزرقاء للمصنع والتي كانت على النحو التالي :
**************************
**************************
**************************
**************************
...
Teva announced Friday that it completed its planned purchase of Cephalon after the European Commission cleared the transaction. Pursuant to the merger agreement, which sees Cephalon become a wholly owned unit of Teva, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.European regulators said that Teva must divest Cephalon's marketing authorisation for a generic version of the narcolepsy drug Provigil (modafinil) in France. Teva also agreed to grant the purchaser "certain additio ...
Pfizer announced that it settled a patent infringement case against Teva, under which the Israeli drugmaker agreed not to launch a generic version of Lipitor (atorvastatin) in the UK until May 2012.According to Pfizer, Teva acknowledged that the patent on Lipitor is valid and would be infringed by its proposed generic version of the product. Teva, along with several other companies, agreed not to sell the generic version of the drug in the UK before patent expiry in May next year. Other terms of the deal were not disclosed. ... 








